JP6845755B2 - 表皮肥厚抑制用皮膚外用剤 - Google Patents
表皮肥厚抑制用皮膚外用剤 Download PDFInfo
- Publication number
- JP6845755B2 JP6845755B2 JP2017126924A JP2017126924A JP6845755B2 JP 6845755 B2 JP6845755 B2 JP 6845755B2 JP 2017126924 A JP2017126924 A JP 2017126924A JP 2017126924 A JP2017126924 A JP 2017126924A JP 6845755 B2 JP6845755 B2 JP 6845755B2
- Authority
- JP
- Japan
- Prior art keywords
- apple
- skin
- epidermal thickening
- human epidermal
- epidermal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000699 topical effect Effects 0.000 title claims 2
- 208000019028 Epidermal thickening Diseases 0.000 title description 19
- 235000013399 edible fruits Nutrition 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 18
- 230000004663 cell proliferation Effects 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 210000001339 epidermal cell Anatomy 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 3
- 239000003966 growth inhibitor Substances 0.000 claims 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims 2
- 235000013824 polyphenols Nutrition 0.000 claims 2
- 210000000270 basal cell Anatomy 0.000 claims 1
- 241000220225 Malus Species 0.000 description 17
- 239000002537 cosmetic Substances 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- 210000002615 epidermis Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 239000012085 test solution Substances 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 206010040867 Skin hypertrophy Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000000035 BCA protein assay Methods 0.000 description 1
- 241000272185 Falco Species 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- -1 etc.) Natural products 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000551 statistical hypothesis test Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Description
アップルフェノン C−100(アサヒフードアンドヘルスケア社)を5%(v/v)ウシ胎児血清(FBS;Life technologies社)を含むダルベッコ改変イーグル培地(DMEM;Life technologies社)に終濃度50μg/mLになるようにそれぞれ溶解し、これを被験溶液とした。同様の方法でコメ抽出物を溶解し、これを比較溶液とした。
10%(v/v)FBSを含むDMEMを用いてHaCaT細胞を懸濁し、35mmシャーレに9.0×105cellsになるように播種した。その後、35mmシャーレを37℃、CO2濃度5%の条件下で24時間培養した。
0.5%(v/v)Triton X−100を含むリン酸緩衝溶液を96ウェル培養プレートの各ウェルに0.05mLずつ添加して細胞を完全に溶解した。各ウェルにPierce BCA Protein Assay Kit(Thermo Fisher Scientific社)のReagent AとReagent Bの比を50:1で混合した溶液を各ウェルに0.05mLずつ添加して1分間シェイカーにかけて混合した。その後、37℃で10分間インキュベートして吸光マイクロプレートリーダーV max(Molecular Device社)を用いて550nmにおける吸光度を測定した。
検量線をもとに、得られた吸光度からタンパク量を算出した。検量線の作成にはウシ血清アルブミン(BSA;Sigma Aldrich社)を用いた。BSA濃度は2、1、0.5、0.25、0.125、0mg/mLの5点とした。後述の結果(1)では、UVAまたはUVBを照射していない時の細胞増殖率をコントロール1、後述の結果(2)では、試料なし且つUVAあるいはUVB照射した時の細胞増殖率をそれぞれコントロール2、コントロール3とした。これらを対照として(細胞増殖率=100%)、それぞれの試料を作用させた時の細胞増殖率を算出した。各条件につき、6以上のウェル数の結果を用いて細胞増殖率の平均値を算出し、後述の統計解析を用いて、有意な差をもって細胞増殖を抑制した場合、表皮肥厚抑制効果があったと判断した。
試験における統計学的有意差検定にはスチューデントのt検定を用いて、対応のない、両側検定の条件で実施した。有意水準は5%とした(p<0.05)。
最初に、UVAまたはUVBを照射した影響により細胞増殖が誘導されるかどうか検討した結果、後述の表1に示すように、UVAまたはUVB非照射(コントロール1)と比較して、UVAまたはUVB照射により細胞増殖率が有意に高まることを確認した。
次に、被験溶液添加時のUVAまたはUVB照射下における細胞増殖率を算出した結果、後述の表2に示すように、試料なし且つUVAあるいはUVB照射(コントロール2及び3)と比較して、実施例1はUVAまたはUVBを照射した影響により誘導される細胞増殖を有意に抑制した。しかし、比較例1は有意な細胞増殖抑制効果は見られなかった。なお、使用した被験溶液の培養細胞に対する毒性は認められなかった。表1及び2が示すように、実施例1の被験溶液はUVAまたはUVB照射の影響による細胞の増殖を有意に抑制した。
Claims (4)
- リンゴ果実抽出物を有効成分として含有することを特徴とする、
紫外線曝露により生じるヒト表皮細胞の増殖抑制剤。
- 前記ヒト表皮細胞は、基底細胞である、
請求項1に記載のヒト表皮細胞の増殖抑制剤。
- 前記ヒト表皮細胞の増殖抑制剤は、局所用外用剤であることを特徴とする
請求項1又は2に記載のヒト表皮細胞の増殖抑制剤。
- 前記リンゴ果実抽出物がリンゴポリフェノールであり、該リンゴポリフェノールを組成物全量に対して0.0005〜1質量%含有する、
請求項1から3のいずれか1項に記載のヒト表皮細胞の増殖抑制剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017126924A JP6845755B2 (ja) | 2017-06-29 | 2017-06-29 | 表皮肥厚抑制用皮膚外用剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017126924A JP6845755B2 (ja) | 2017-06-29 | 2017-06-29 | 表皮肥厚抑制用皮膚外用剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019011256A JP2019011256A (ja) | 2019-01-24 |
JP6845755B2 true JP6845755B2 (ja) | 2021-03-24 |
Family
ID=65227311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017126924A Active JP6845755B2 (ja) | 2017-06-29 | 2017-06-29 | 表皮肥厚抑制用皮膚外用剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6845755B2 (ja) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010254667A (ja) * | 2009-03-31 | 2010-11-11 | Fancl Corp | コラーゲンゲル収縮剤 |
JP6158471B2 (ja) * | 2011-12-28 | 2017-07-05 | 片倉コープアグリ株式会社 | 皮膚老化抑制剤 |
JP2013209302A (ja) * | 2012-03-30 | 2013-10-10 | Kose Corp | リンゴ幼果抽出物を含む表皮幹細胞性維持剤 |
-
2017
- 2017-06-29 JP JP2017126924A patent/JP6845755B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2019011256A (ja) | 2019-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103479538B (zh) | 含有人参的花或人参的种子提取物的皮肤外用剂组合物 | |
US10092495B2 (en) | Use of a composition comprising avocado perseose in the protection of epidermal stem cells | |
CN102421412B (zh) | 含有日本扁柏多糖的皮肤外用组合物 | |
KR101824770B1 (ko) | 적하수오 부정근 추출물을 함유하는 피부 주름개선 기능성 화장료 조성물 | |
KR20230147028A (ko) | 대마 줄기 추출물을 유효성분으로 포함하는 항노화, 항염 또는 피부재생용 조성물 | |
JP5921056B2 (ja) | 美容用組成物 | |
US20220249355A1 (en) | Cosmetic care method based on photoactive extracts of microalgae | |
KR20130088997A (ko) | 생캐비어 추출물 및 발효추출물을 이용한 육모, 발모, 탈모방지 및 두피 개선용 화장료 조성물 | |
JP6845755B2 (ja) | 表皮肥厚抑制用皮膚外用剤 | |
JP2012206957A (ja) | コラーゲン産生促進剤 | |
KR101303807B1 (ko) | 항노화 화장료 조성물 | |
KR20140095122A (ko) | 보리 추출물 또는 에리오딕티올을 포함하는 콜라겐 분해 방지 또는 콜라겐 합성 촉진용 조성물 | |
KR101172058B1 (ko) | 피부주름 개선 및 탄력 증진용 피부 외용제 조성물 | |
CN102056585B (zh) | 用于改善皮肤皱纹或皮肤增白的皮肤外用组合物 | |
JP5144362B2 (ja) | 皮膚外用剤 | |
JP5259127B2 (ja) | ツツジ科エリカ属植物由来成分を少なくとも含む外皮系組織用組成物 | |
US20210338755A1 (en) | Aqueous extract from cells of fitzroya cupressoides (alerce) with anti- aging and skin regeneration properties | |
JP5689552B1 (ja) | 特定の波長域を有する光を照射して栽培したカモミールの抽出物を含有する皮膚外用剤や内用剤。 | |
KR101618595B1 (ko) | 토마티딘을 함유하는 미숙 토마토 분해물 제조 방법 및 이를 함유하는 화장료 조성물 | |
CN103491943A (zh) | 包含榕树、莲属植物和三叶草浆液级分的组合物(老化) | |
Heo et al. | Pre-Clinical evaluation of proprietary lutein, zeaxanthin, and rosemary formulation for its dermal protective activity in male swiss albino mice | |
JP2019011253A (ja) | 表皮肥厚抑制剤 | |
JP2019011252A (ja) | 表皮肥厚抑制剤 | |
KR102109829B1 (ko) | 화장료 조성물 | |
KR20130057534A (ko) | 아사이베리 추출물 및 새싹 추출물을 함유하는 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190621 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200707 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200904 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200907 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210202 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210226 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6845755 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |